David A. Siegel Enanta Pharmaceuticals Inc Transaction History
Two Sigma Advisers, LP
- $47 Billion
- Q3 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Enanta Pharmaceuticals Inc stock. As of the latest transaction made, Two Sigma Advisers, LP holds 125,100 shares of ENTA stock, worth $1.51 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
125,100
Previous 133,600
6.36%
Holding current value
$1.51 Million
Previous $1.01 Million
48.22%
% of portfolio
0.0%
Previous 0.0%
Shares
32 transactions
Others Institutions Holding ENTA
# of Institutions
128Shares Held
19.4MCall Options Held
290KPut Options Held
61.7K-
Farallon Capital Management LLC San Francisco, CA2.12MShares$25.6 Million0.11% of portfolio
-
Krensavage Asset Management, LLC New York, NY2.11MShares$25.5 Million10.78% of portfolio
-
Janus Henderson Group PLC London, X01.95MShares$23.5 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.94MShares$23.4 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.85MShares$22.3 Million0.0% of portfolio
About ENANTA PHARMACEUTICALS INC
- Ticker ENTA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,724,900
- Market Cap $250M
- Description
- Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and li...